For years, the development of drugs for respiratory diseases, mainly asthma and chronic obstructive pulmonary disease (COPD), have relied on the administration of a new drug, mostly by inhalation and assessment by physiologic tests and questionnaires. More and more these new drugs are administered in fixed combinations.
This white paper outlines the latest respiratory R&D trends encompassing outcomes and clinical trial study designs.
Abu Dahab Complex, Nufan As-Saoud Al-Edwan St. 22, 5th Floor,
P.O.Box 930388, 11193,
Amman, Jordan